| Nov 11 |
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
|
| Oct 29 |
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
|
| Oct 23 |
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
|
| Sep 18 |
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
|
| Sep 17 |
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
|
| Sep 17 |
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
|
| Sep 16 |
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
|
| Sep 13 |
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
|
| Aug 30 |
Aptevo Therapeutics files to sell 13.51M shares of common stock
|
| Aug 8 |
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
|
